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Abstract
Background: The majority of Crohn's disease patients with B1 phenotype at diagnosis (i.e. non-
stricturing non-penetrating disease) will develop over time a stricturing or a penetrating pattern.
Conflicting data exist on the rate of proximal disease extension in ulcerative colitis patients with
proctitis or left-sided colitis at diagnosis. We aimed to study disease evolution in Crohn's disease
B1 patients and ulcerative colitis patients with proctitis and left-sided colitis at diagnosis.
Methods: 116 Crohn's disease and 256 ulcerative colitis patients were followed-up for at least 5
years after diagnosis. Crohn's disease patients were classified according to the Vienna criteria. Data
were analysed actuarially.
Results: B1 phenotype accounted for 68.9% of Crohn's disease patients at diagnosis. The
cumulative probability of change in disease behaviour in B1 patients was 43.6% at 10 years after
diagnosis. Active smoking (Hazard Ratio: 3.01) and non-colonic disease (non-L2) (Hazard Ratio:
3.01) were associated with behavioural change in B1 patients. Proctitis and left-sided colitis
accounted for 24.2%, and 48.4% of ulcerative colitis patients at diagnosis. The 10 year cumulative
probability of proximal disease extension in patients with proctitis and left-sided colitis was 36.8%,
and 17.1%, respectively (p: 0.003). Among proctitis patients, proximal extension was more
common in non-smokers (Hazard Ratio: 4.39).
Conclusion: Classification of Crohn's disease patients in B1 phenotype should be considered as
temporary. Smoking and non-colonic disease are risk factors for behavioural change in B1 Crohn's
disease patients. Proximal extension is more common in ulcerative colitis patients with proctitis
than in those with left-sided colitis. Among proctitis patients, proximal extension is more common
in non-smokers.
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Inflammatory bowel diseases (IBD) are chronic heteroge-
neous disorders with unpredictable clinical course. Stud-
ies on Crohn's disease (CD) behaviour have been
hampered by the variability of classifications used and by
their unsatisfactory degree of inter-rater agreement [1-4].
The Vienna classification of CD [5] has been proposed in
an effort to stratify patients on the basis of widely accepted
and reproducible criteria [6]. Although CD location, as
defined by the Vienna classification is a relatively stable
phenotype, its behaviour varies over time [7]. The major-
ity of patients with B1 phenotype (i.e. non-stricturing
non-penetrating disease) will develop over time a strictur-
ing or a penetrating pattern (i.e. B2 and B3 respectively)
[7-11]. The environmental and genetic factors affecting
disease behaviour evolution are not fully characterized.
Ileal location (i.e. L1) [8,9,11], active smoking [8] and
number of flares per year [8] were reported to be the major
determinants of phenotypic changes. Moreover, some
authors suggested that intra-abdominal penetrating dis-
ease (IAPD) and perianal penetrating disease (PAPD) rep-
resent distinct clinic entities which should be studied
independently [8,11].
The extent of colonic involvement in ulcerative colitis
(UC) patients is clinically relevant because it has some
bearing on the severity of disease and on the needs for
medical supervision, drug therapy and surgical excision
[12-14]. Although in certain patients with proctitis and
left-sided UC, the inflammation spreads proximally, stud-
ies on the stability of disease extent over time and risk fac-
tors influencing disease extent progression have failed to
offer conclusive information [12-21].
We aimed to study the long-term outcome of a homoge-
neous and well-defined group of Cretan patients with
IBD. Particular emphasis was given on the study of rate
and risk factors that might influence: change of disease
behaviour over time in B1 CD patients; and proximal dis-
ease extension in UC patients with proctitis and left-sided
colitis at diagnosis;
Methods
The Gastroenterology Department of the University Hos-
pital of Heraklion has previously conducted prospective
and population-based epidemiologic studies of UC and
CD in the prefecture of Heraklion, and participated in the
European collaborative study of IBD (EC-IBD) [22-26].
The patient cohort seen at the aforementioned institution
has been enriched with cases followed-up at the Gastroen-
terology Department of Venizelion General Hospital of
Heraklion (since its opening at 1996). During the study
period these two units were the sole centers providing
health care for patients with GI tract problems living in
the island of Crete (approximately 600 000 people). Clin-
ical details were collected in a special designed form, by
patient interview and case note review. Our study proto-
col was approved by the Ethics Committee of the Medical
School of the University of Crete. Written consent was
obtained from the patients.
Of the 736 patients listed in the IBD registry (498 with UC
and 238 with CD), 372 (256 with UC and 116 with CD)
met the following criteria for inclusion in this analysis:
1. A confirmed diagnosis of UC or CD by standard clini-
cal, radiologic, endoscopic and histologic criteria. Patients
with an initial diagnosis of UC later changed to CD or vice
versa were included in the analysis with the final diagno-
sis.
2. A satisfactory assessment of the extent of disease at the
initial examination in patients with UC and of disease
behaviour at diagnosis in patients with CD. Extent, loca-
tion, and behaviour of UC and CD were evaluated by ileo-
colonoscopy, upper GI tract endoscopy, enteroclysis, CT
scan of abdomen and surgical reports.
3. A follow-up period of at least 60 months. Time of diag-
nosis was defined as the date of first detection of unequiv-
ocal inflammatory abnormalities of the intestine, as
assessed from radiologic, endoscopic, or operative obser-
vations [9].
The extent of UC was defined as proctitis (rectum involve-
ment), left-sided colitis (involvement up to the splenic
flexure) and extensive colitis (involvement proximal to
the splenic flexure). Proximal disease extension was
defined as the finding at any follow-up colonoscopy of
macroscopic inflammation extending beyond 15 cm from
the anus in case of proctitis or beyond the splenic flexure
in case of left-sided colitis.
The clinical classification of patients with CD was carried
out in strict accordance with the Vienna criteria [5]. In
patients with B1 phenotype at diagnosis the first morpho-
logic demonstration of narrowing or penetrating compli-
cation was used to mark the occurrence of the
complication. Some patients had stricturing disease and
then developed a fistula. The sequence was taken into
account (i.e. B2 then B3 disease) when the time interval
between the two events was greater than one year, other-
wise the disease was considered as B3 [9]. According to
previous analyses, patients who were diagnosed with
PAPD before CD diagnosis were assumed to have devel-
oped their fistula on the day after diagnosis [27]. Only
major operations (i.e. bowel resections) were considered
as surgical therapy in patients with CD.Page 2 of 10
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and had easy access in flare-up episodes. At each visit,
symptoms and signs, laboratory and diagnostic examina-
tions, medications and surgery were prospectively regis-
tered on a predesigned data sheet. Asymptomatic patients
were fully investigated on a yearly basis. Finally, an assess-
ment was made for each year of follow-up, comprising the
clinical activity within the year, disease course, intestinal
complications, extent of disease, diagnostic procedures,
medical treatments, operations, hospitalizations, and out-
patient visits.
Chronic continuous course was defined as continuous
activity within and during each year of follow-up [28].
Patients were defined as smokers if they consumed at least
7 cigarettes/week and non-smokers if they had never
smoked or had stopped smoking before diagnosis [8]. A
familial form of the disease was defined as the presence of
UC or CD in a relative, whatever the familial degree (i.e.
parent, child, sibling, grandparent, grandchild, aunt,
uncle, and cousin).
Statistical analysis
Descriptive statistics are expressed as mean and standard
deviation or as frequency counts and percentages. Cate-
gorical data were analyzed using Pearson's chi-square test.
Equalities of means and proportions were tested using
Student's t test and analysis of variance with Bonferroni
correction for group comparisons. P values of less than
0.05 were considered statistically significant.
Survival analyses, using the Kaplan-Meier method with
log-rank test [29,30], and Cox's proportional hazards
model for multivariate analyses [31] were used to study
the predefined end-points. Patients with UC were
included in these calculations only as long as they had not
undergone colectomy. Patients not reaching the end point
under consideration were censored at the time of the last
clinical follow-up. The multivariate analysis was applied
to those of the variables having a p = 0.2 in order to iden-
tify possible confounding effects [32]. In the multivariate
procedure, p = 0.05 was considered as the level of signifi-
cance. Results of analysis are presented as hazard ratios
(HR) with 95% confidence intervals (95% CI). The fol-
lowing variables suspected as possible predictors were
included in the analysis: age at diagnosis, months from
onset to diagnosis, sex, positive family history of IBD,
active smoking, disease location in patients with CD, need
for immunosuppressive therapy, chronic continuous
course, and previous major operation in patients with CD.
To examine an age-related effect, patients with CD were
classified as the A1/A2 Vienna classification of under or
over 40 years of age. Continuous variables (i.e. age at diag-
nosis in patients with UC and months from onset to diag-
nosis in patients with UC and CD) were dichotomized by
splitting mean values, which were then compared.
Results
Crohn's disease patients
A total of 116 patients with CD were included in the study
(Table 1). B1 phenotype accounted for 68.9% of CD
Table 1: Demographic and clinical parameters depending on Crohn's disease behaviour at diagnosis
Disease behaviour at diagnosis
Variable B1 (N = 80) B2 (N = 15) B3 (N = 21) Overall (N = 116)
Follow-up (yr) 10.8 ± 6.5 9.9 ± 4 10.4 ± 6.9 10.5 ± 6.4
Males 46 (57.5%) 12 (80%) 12 (57.1%) 70 (60.3%)
Months to diagnosis 44.6 ± 42.4 38.8 ± 45.9 26.2 ± 36.1 40.6 ± 42.1
A1 60 (75%) 9 (60%) 14 (66.6%) 83 (71.5%)
Positive family history 10 (12.5%) 2 (13.3%) 3 (14.2%) 17 (14.6%)
Location of disease
L1 12 (15%) 7 (46.6%)* 6 (28.5%) 25 (21.5%)
L2 25 (31.2%) 2 (13.3%) 3 (14.2%) 30 (25.8%)
L3 34 (42.5%) 5 (33.3%) 12 (57.1%) 51 (43.9%)
L4 9 (11.2%) 1 (6.6%) 0 10 (8.6%)
Current smoking 41 (51.2%) 6 (40%) 12 (57.1%) 59 (50.8%)
Continuous course 17 (21.2%) 3 (20%) 3 (14.2%) 23 (19.8%)
Extraintestinal disease‡ 43 (53.7%) 6 (40%) 8 (38%) 57 (49.1%)
Immunosuppressives 38 (47.5%) 3 (20%)* 9 (42.8%) 50 (43.1%)
Major operations† 14 (17.5%) 11 (73.3%)* 10 (47.6%)* 35 (30.1%)
At diagnosis 2 (2.5%) 9 (60%)* 7 (33.3%)* 18 (15.5%)
After diagnosis 12 (15%) 2 (13.3%) 3 (14.2%) 17 (14.6%)
Values are given as mean ± SD or number of patients; Values in parentheses are percentages; N, number; A1, age at diagnosis ≤ 40 years; B1, non-
stricturing non-penetrating disease; B2, stricturing disease; B3, penetrating disease; L1, ileal location; L2, colonic location; L3, ileo-colonic location; 
L4, disease in the upper gastro-intestinal tract; ‡Extraintestinal disease refers to manifestations recorded during the entire follow-up period; †Major 
operations refer to bowel resections; *P < 0.05 vs B1;Page 3 of 10
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years after diagnosis (i.e. 64 patients), and for 36.8% of
cases at the end of the study (i.e. 42 patients). Eleven
patients with B1 behaviour at diagnosis (13.7%) devel-
oped B2 disease, whereas 27 patients (33.7%) developed
B3 disease. Survival analysis showed that 10 years after
diagnosis, the proportion of CD patients still remaining
B1 was 38.9% (± Standard Error (SE): 4.9%). The cumula-
tive probability of disease behaviour reclassification in
patients with B1 phenotype at diagnosis was 43.6% (± SE:
6.1%) at 10 years after diagnosis (Figure 1).
Factors associated with phenotype change in patients with
B1 disease at diagnosis as identified in univariate analysis
are listed in table 2. Regression model analysis selected
active smoking (HR: 3.01; 95% CI: 1.40–6.45; P: 0.005)
and non-L2 disease (HR: 3.01; 95% CI: 1.16–7.78; P:
0.023) as significantly associated with B2 and B3 reclassi-
fication in patients with B1 phenotype at diagnosis. Active
smoking (HR: 3.84; 95% CI: 1.00–14.72; P: 0.049) and L1
disease (HR: 5.76; 95% CI: 1.65–20.11; P: 0.006) were
selected as significantly associated with reclassification
from B1 to B2 phenotype, whereas, active smoking (HR:
3.68; 95% CI: 1.45–9.29; P: 0.006) and non-L2 disease
(HR: 3.74; 95% CI: 1.11–12.56; P: 0.033) were selected as
significantly associated with reclassification from B1 to B3
phenotype.
Fifteen patients with initially B1 phenotype (18.7%)
developed IAPD and 12 patients (15%) PAPD. Regression
model analysis selected active smoking (HR: 5.18; 95%
CI: 1.12–23.96; P: 0.035), L1 disease (HR: 5.87; 95% CI:
1.41–24.42; P: 0.015) and chronic continuous course
(HR: 4.56; 95% CI: 1.25–16.61; P: 0.021) as significantly
associated with the development of IAPD in patients with
initially B1 phenotype. In univariate analysis the only fac-
tor significantly associated with reclassification from B1 to
PAPD was active smoking (P: 0.049), which was however
rejected from the regression model (HR: 3.21; 95% CI:
0.96–10.71; P: 0.058) when it was combined with other
variables having a p value between 0.51–0.2.
None of our B1 patients reclassified as B2 became B3,
whereas 3 out of 15 patients with B2 phenotype at diag-
nosis became B3. The cumulative probability of B3 reclas-
sification in patients with B2 phenotype at diagnosis was
27.8% (± SE: 15.1%) at 10 years after diagnosis (Figure 1).
At the end of follow-up, 51 patients had B3 phenotype.
Overall, B3 phenotype remained unchanged in 23
patients with IAPD and 17 patients with PAPD. However,
5 out of 28 patients (17.8%) with IAPD developed subse-
quently PAPD, and 6 out of 23 patients (26%) with PAPD
developed subsequently IAPD. The cumulative probabil-
ity of appearance of the other penetrating phenotype in an
already B3 patient was 22.7% (± SE: 6.7%) and 32.4% (±
SE: 10.8%) at 5 and 10 years, respectively. The probability
of appearance of PAPD in patients with IAPD was not
related to age at diagnosis, disease location, or active
smoking. Similarly, the probability of appearance of IAPD
in patients with PAPD was not related to age at diagnosis
or active smoking. Although this was also the case for
patients with L1, L2 and L4 disease, L3 patients with
PAPD had a greater risk of developing IAPD (P: 0.021).
At 5 years of follow-up, 23 out of 116 CD patients
(19.8%) had experienced a major surgery. The cumulative
probability of surgery was 29.7% (± SE: 4.6%) at 10 years
after diagnosis. Patients with L2 disease had a lower risk
of surgery than patients with L1 (P: < 0.001), L3 (P:
0.011), and L4 disease (P: 0.026). The risk of surgery was
also higher in current smokers (P: < 0.001). As shown in
figure 2, the risk of surgery was significantly higher in
patients with current B2 and B3 phenotypes when com-
pared to that of patients with current B1 phenotype,
whereas the difference between B2 and B3 curves was
insignificant.
Six patients underwent a second operation. The cumula-
tive probability of 2nd intestinal resection was 7.4% (± SE:
5%) and 17.2% (± SE: 7.9%) at 5 and 10 years after 1st
intestinal resection, respectively.
Ulcerative colitis patients
A total of 256 patients with UC were included in the study
(Table 3). During follow-up, proximal disease extension
Kaplan-Meier estimates of remaining free of change of dis-ease behaviour in p ients with B1 and B2 phenotypes at di gnosisFigur  1
Kaplan-Meier estimates of remaining free of change of dis-
ease behaviour in patients with B1 and B2 phenotypes at 
diagnosis. The numbers in parentheses (after years from IBD 
diagnosis) refer to the numbers of patients at risk at the cor-
responding time points. Log-rank test p value: 0.073.Page 4 of 10
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proctitis and in 26 out of 124 patients (20.9%) with left-
sided colitis. At 5 years of follow-up, proximal extension
was documented in 11 out of 62 patients with proctitis
(17.7%) and in 7 out of 124 patients with left-sided colitis
(5.6%). The cumulative probability of proximal extension
in patients with proctitis was 36.8% (± SE: 7.1%) at 10
years after diagnosis (Figure 3). In contrast, the cumula-
tive probability of proximal extension in patients with
left-sided colitis was significantly lower, 17.1% (± SE:
3.8%) at 10 years after diagnosis (Figure 3). None of our
proctitis patients eventually underwent colectomy. In
contrast, one patient with left-sided colitis at diagnosis
and proximal disease extension during follow-up, and
two other left-sided colitis patients without further spread
of the disease within the observation period were oper-
ated on. The 10 year cumulative probability of surgery in
our ulcerative colitis patient cohort was 2.9% (± SE: 1.7%)
(years refer to time interval after the initial 5 year period
of minimum follow-up from diagnosis), whereas, the
cumulative probability of colorectal cancer was 4.5% (±
SE: 3.6%) at 20 years
Factors associated with disease progression in proctitis
patients as identified in univariate analysis are listed in
table 4. Regression model analysis selected non-smoking
as significantly associated with disease progression in
patients with proctitis (HR: 4.39; 95% CI: 1.02–18.79; P:
0.046). None of the variables under study was signifi-
cantly associated with disease progression in patients with
left-sided colitis.
Discussion
Many patients with severe GI problems from other parts
of mainland Greece seek medical care in Athens, thus by
strict criteria the patients included in series originating
from referral Athenian hospitals cannot be considered to
be a representative sample for all cases with IBD in Greece
[33-37]. It is a well known fact that patients with benign
clinical course are under-represented at a tertiary referral
center [38]. The advantage of the present study is that, our
population is dispersed over a small geographical area
and referred to only two Gastroenterology Units which
have registered practically all patients with IBD in Crete.
Crohn's disease
There is only one study analyzing the natural history of
CD in Greece [33]. In this series, only crude rates were
reported, and emphasis was given on disease location, not
behaviour.
Progression over time of CD pathologic changes has been
suggested in a previous report by Kelly et al [39]. Other
series, using the Vienna [7,9,11] or other classifications
[27,40] have also focused on the changing nature of CD
over time. Although our results fit well with those previ-
ously reported, they should be interpreted with caution as
only 22 patients with B1 behaviour and 5 patients with B2
behaviour were available for follow-up at 10 years after
diagnosis. Some authors found that patients who are clas-
sified as B2 at diagnosis tend to remain B2 over time
[8,41]. Although these observations are suggestive more
of a parallel than of a sequential progression from B1 to
Table 2: Univariate analysis of risk of change of disease behaviour in patients with B1 disease at diagnosis
Patients without change of disease behaviour 
(N = 42)
Patients with change of disease behaviour 
(N = 38)
P§
Males 26 (61.9%) 20 (52.6%) 0.180†
Months to diagnosis 49.2 ± 43.5 39.6 ± 41.2 NS
A1 29 (69%) 31 (81.5%) 0.147†
Positive family history 4 (9.5%) 6 (15.7%) NS
Location of disease
L1 3 (11.9%) 9 (23.6%) 0.005
L2 20 (47.6%) 5 (13.1%) 0.006
L3 15 (35.7 %) 19 (50%) NS
L4 4 (9.5%) 5 (13.1%) NS
Current smoking 13 (30.9%) 28 (73.6%) 0.001
Continuous course 4 (9.5%) 13 (34.2%) 0.016
Immunosuppressives 11 (26.1%) 9 (23.6%)* NS
Surgery at diagnosis‡ 1 (2.3%) 1 (2.6%) NS
Values are given as mean ± SD or number of patients; Values in parentheses are percentages; N, number; A1, age at diagnosis ≤ 40 years; L1, ileal 
location; L2, colonic location; L3, ileo-colonic location; L4, disease of the upper gastro-intestinal tract; *Data collected until change of disease 
behavior; §P values from survival analysis using log-rank test; ‡Surgery at diagnosis refers to bowel resections; †Variables having a p value between 
0.51 and 0.2, although insignificant, were included in the regression analysis to avoid confounding effects;Page 5 of 10
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some patients with stricturing behaviour at presentation
will finally develop penetrating disease [8,41,42].
An important factor for determining disease behaviour is
the location of lesions. In our series, active smoking and
L1 or non-L2 disease were associated with change of dis-
ease behaviour in patients with B1 phenotype at diagno-
sis. Location and smoking have also been reported by
others as factors associated with complicated CD
[8,9,11,40,43,44]. Tobacco use has been a risk factor for
ileal rather than colonic-only disease [45-47].
The cumulative probability of surgery in our CD patients
was lower than that reported in other series [48-51]. Once
again, our results should be interpreted with caution as
only 43 patients were available for follow-up at 10 years
after diagnosis. As expected, the probability of surgery was
significantly higher in patients with either B2 or B3 phe-
notypes (Figure 2). The probability of surgery in B1
patients without change of disease behaviour was mini-
mal, a finding quite similar to that previously reported by
others [11,49]. Smoking has been previously shown to be
associated with increased risk of surgery in CD patients
[40,45,47,52,53]. The lower probability of surgery in
patients with colonic disease has been previously reported
by other authors using different classifications
[40,48,50,54,55].
The risk for a second resection in our patients previously
operated on for CD was lower than that reported in other
series [53,56]. Previous reports using different classifica-
tions identified more frequent reoperation in those with
perforating disease [1,57,58], but others have failed to
confirm this association [59,60].
Both intra-abdominal and perianal fistulas were classified
by the Vienna Working Party Group as penetrating disease
[5]. However, some studies suggested that they represent
distinct entities [8,11,61]. We found that in a significant
proportion of B3 patients both penetrating phenotypes
appear. Although this was also the case in other reports, in
some series no data were clearly reported [27,62], whereas
in other series only crude rates were reported
[8,9,11,49,63].
Ulcerative colitis
There are four Athenian studies investigating the clinical
course of UC [34-37]. In all these series only crude rates
were reported. The age and distribution of macroscopic
inflammation at presentation in our patient cohort fits
well with that reported in other series [25,26]. The rate of
Kaplan-Meier estimates of remaining free of proximal disease extension in patients with proctit s and left-sided colitis at di gnosisFigure 3
Kaplan-Meier estimates of remaining free of proximal disease 
extension in patients with proctitis and left-sided colitis at 
diagnosis. The numbers in parentheses (after years from IBD 
diagnosis) refer to the numbers of patients at risk at the cor-
responding time points. Log-rank test p value: 0.003.
Kaplan-Meier estimates of remaining free of surgery with regard to cu r nt dis ase behav ourFi ure 2
Kaplan-Meier estimates of remaining free of surgery with 
regard to current disease behaviour. In patients with B1 dis-
ease (upper curve), years refer to years after diagnosis in 
those with stable behaviour, and to years until change of 
behaviour in those reclassified; In patients with B2 disease 
(lower curve), years refer to years after diagnosis in cases 
with stable B2 phenotype, and to years after change of dis-
ease behaviour from B1 to B2 in those reclassified; In 
patients with B3 disease (middle curve), years refer to years 
after diagnosis in cases with initial B3 phenotype, and to 
years after change of disease behaviour form B1 or B2 to B3 
in those reclassified; The numbers in parentheses (after years 
from IBD diagnosis) refer to the numbers of patients at risk 
at the corresponding time points. The corresponding log-
rank test p values are: <0.001 (B1 vs B2), <0.001 (B1 vs B3), 
0.359 (B2 vs B3).Page 6 of 10
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cially when compared to other much larger series [12].
However, the rate of colectomy after 5 years is well known
to be quite small, about 1% per year [64,65], and this low
rate of colectomy equally applies to patients with initial
distal disease and those with initial pancolitis [64]. The
cumulative probability of colorectal cancer in our patients
falls within the wide confidence intervals calculated by
others [65,66].
Conflicting data exist on the rate of proximal disease
extension of ulcerative proctitis. [13-16,20,21]. When
considering only those two studies in which diagnosis
and disease progression were confirmed using endoscopy
and survival analysis was carried out, the cumulative rates
of proximal extension was reported to range between 30
and 54% at 10 years, and between 50% and 84% at 20
years after diagnosis [20,21]. Our results fit well with
those previously reported, however only 19 patients with
proctitis at diagnosis were available for follow-up at 10
years after diagnosis. We found that the risk of progression
was higher in non-smokers, a finding previously con-
firmed by some [18,20] but not all authors [13]. There are
several possible explanations for these conflicting results.
Some are related to differences in disease extent definition
(true proctitis [15,18-21] vs proctosigmoiditis [12-14])
and means of follow-up surveillance (endoscopic [17,19-
21] vs radiologic [18] vs a combination of sigmodoscopy
and barium enema [12-15]). Furthermore, there is poor
agreement between extent assessed by histology and
endoscopy both at diagnosis and at follow-up [17,19,25].
Fifty eight of our ulcerative colitis patients were available
for follow-up at 10 years after diagnosis. Thus, we have
found the cumulative probability of proximal extension
in these patients to be 17.1% at 10 years after diagnosis.
Others reported cumulative rates ranging between 14%
and 32% at 10 years after diagnosis [13,14]. However,
these figures were evaluated using barium enemas and cal-
culated for mixed groups of patients with proctitis and
procto-sigmoiditis [13], or with left-sided and extensive
colitis at diagnosis [14]. We were unable to find a single
demographic or clinical factor associated with change of
disease extent from left-sided to extensive colitis.
Conclusion
Classification of Crohn's disease patients in B1 phenotype
should be considered as temporary. Smoking and non-
Table 4: Univariate analysis of overall risk for proximal extension in patients with proctitis at diagnosis
Patients with disease progression (N = 25) Patients without disease progression (N = 37) P §
Males 15 (60%) 24 (64.8%) NS
Urban residence 19 (76%) 21 (56.7%) 0.200†
Months to diagnosis 21 ± 50.4 27.1 ± 31.7 0.125†
Age at diagnosis (yr) 43.8 ± 15.4 34.6 ± 13.4 NS
Positive family history 2 (8%) 6 (16.2%) NS
Current smoking 2 (8%) 14 (37.8%) 0.042
Previous appendectomy 2 (8%) 2 (5.4%) NS
Chronic continuous course 3 (12%) 1 (2.7%) 0.189†
Immunosuppressive drugs 0* 1 (2.7%) NS
Values are given as mean ± SD or number of patients; Values in parentheses are percentages; N, number; *Data collected until change of disease 
extent; §P values from survival analysis using log-rank test; †Variables having a p value between 0.51 and 0.2, although insignificant, were included in 
the regression analysis to avoid confounding effects;
Table 3: Demographic and clinical parameters depending on ulcerative colitis extent at diagnosis
Variable Proctitis (N = 62) Left-sided colitis (N = 124) Extensive colitis (N = 70) Overall (N = 256)
Follow-up (yr) 11.3 ± 7.4 12.5 ± 7.1 12.5 ± 8.2 12.2 ± 7.5
Males 39 (62.9%) 73 (58.8%) 42 (60%) 154 (60.1%)
Months to diagnosis 24.6 ± 40 8.9 ± 13.7* 7.7 ± 15.8* 12.4 ± 24.3
Age at diagnosis (yr) 38.3 ± 14.8 43.3 ± 15.6 40.3 ± 16.3 41.3 ± 15.7
Positive family history 8 (12.9%) 17 (13.7%) 9 (12.8%) 34 (13.2%)
Current smoking 16 (25.8%) 20 (16.1%) 15 (21.4%) 51 (19.9%)
Continuous course 4 (6.4%) 9 (7.2%) 13 (18.5%)*‡ 26 (10.1%)
Extraintestinal disease† 11 (17.7%) 27 (21.7%) 16 (22.8%) 54 (21%)
Immunosuppressives 3 (4.8%) 12 (9.6%) 16 (22.8%)*‡ 31 (12.1%)
Surgery 0 3 (2.4%) 3 (4.2%) 6 (2.3%)
Values are given as mean ± SD or number of patients; Values in parentheses are percentages; N, number; †Extraintestinal disease refers to 
manifestations recorded during the entire follow-up period; *P < 0.05 vs proctitis; ‡ P < 0.05 vs left-sided colitis;Page 7 of 10
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B1 Crohn's disease patients. At least some patients with
stricturing behaviour will finally develop penetrating dis-
ease. In a significant proportion of B3 patients both pene-
trating phenotypes appear. Proximal extension is more
common in ulcerative colitis patients with proctitis than
in those with left-sided colitis. Among proctitis patients,
proximal extension is more common in non-smokers.
Further studies are required to identify factors associated
with proximal disease extension in ulcerative colitis
patients with left-sided colitis at diagnosis.
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